These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11849919)

  • 1. Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.
    Magyar K; Lengyel J; Bolehovszky A; Grézal G; Klebovich I
    Eur J Pharm Sci; 2002 Mar; 15(2):217-23. PubMed ID: 11849919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of deramciclane (EGIS-3886) in rat brain regions.
    Magyar K; Lengyel J; Klebovich I; Urmös I; Grézal G
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):125-31. PubMed ID: 9725469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat.
    Nemes KB; Abermann M; Bojti E; Grézal G; Al-Behaisi S; Klebovich I
    J Pharm Pharmacol; 2000 Jan; 52(1):47-51. PubMed ID: 10716602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits.
    Lengyel J; Bolehovszky A; Klebovich I; Aberman M; Magyar K
    Arzneimittelforschung; 1998 May; 48(5):455-60. PubMed ID: 9638311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of deramciclane in rabbits.
    Lengyel J; Bojti E; Bolehovszky A; Grézal G; Klebovich I; Magyar K
    Arzneimittelforschung; 1998 Nov; 48(11):1063-8. PubMed ID: 9850425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing.
    Kanerva H; Huuskonen H; Alhonen-Raatesalmi A; Nevalainen T; Urtti A
    Biopharm Drug Dispos; 1998 Nov; 19(8):531-9. PubMed ID: 9840215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.
    Huupponen R; Paija O; Salonen M; Björklund H; Rouru J; Anttila M
    Drugs R D; 2003; 4(6):339-45. PubMed ID: 14584962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of deramciclane during multiple oral dosing.
    Kanerva H; Kilkku O; Helminen A; Rouru J; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):589-97. PubMed ID: 10599951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers.
    Kanerva H; Kilkku O; Heinonen E; Helminen A; Rouru J; Tarpila S; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
    Biopharm Drug Dispos; 1999 Oct; 20(7):327-34. PubMed ID: 10760840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different absorption profiles of deramciclane in man and in dog.
    Kanerva H; Klebovich I; Drabant S; Urtti A; Nevalainen T
    J Pharm Pharmacol; 1998 Oct; 50(10):1087-93. PubMed ID: 9821653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.
    Huupponen R; Anttila M; Rouru J; Kanerva H; Miettinen T; Scheinin M
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):449-55. PubMed ID: 15366325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.
    Monostory K; Kohalmy K; Ludányi K; Czira G; Holly S; Vereczkey L; Urmös I; Klebovich I; Kóbori L
    Drug Metab Dispos; 2005 Nov; 33(11):1708-16. PubMed ID: 16118331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CYP2E1 in deramciclane metabolism.
    Monostory K; Köhalmy K; Hazai E; Vereczkey L; Kóbori L
    Drug Metab Dispos; 2005 Nov; 33(11):1717-22. PubMed ID: 15932955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.
    Al-Behaisi S; Antal I; Morovján G; Szúnyog J; Drabant S; Marton S; Klebovich I
    Eur J Pharm Sci; 2002 Mar; 15(2):157-62. PubMed ID: 11849912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of overpressured layer chromatography combined with digital autoradiography and mass spectrometry in the study of deramciclane metabolism.
    Ludányi K; Vékey K; Szúnyog J; Mincsovics E; Karancsi T; Ujszászy K; Nemes KB; Klebovich I
    J AOAC Int; 1999; 82(2):231-8. PubMed ID: 10191528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
    Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J
    Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemistry and enantiomeric purity of a novel anxiolytic agent, deramciclane fumarate.
    Ladányi L; Sztruhár I; Budai Z; Lukács G; Mezei T; Argay G; Kálmán A; Simig G
    Chirality; 1999; 11(9):689-93. PubMed ID: 10506429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.
    Drabant S; Nemes KB; Horváth V; Tolokán A; Grézal G; Anttila M; Gachályi B; Kanerva H; Al-Behaisi S; Horvai G; Klebovich I
    Eur J Pharm Biopharm; 2004 Nov; 58(3):689-95. PubMed ID: 15451546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
    Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body autoradiography and quantitative organ-level distribution study of deramciclane in rats.
    Hazai I; Pátfalusi M; Klebovich I; Urmös I
    J Pharm Pharmacol; 1999 Feb; 51(2):165-74. PubMed ID: 10217315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.